newsfilter
← Latest News
Business Wire·

Longboard Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Corporate Updates

Bexicaserin (LP352) received Breakthrough Therapy designation (BTD) for the treatment of seizures associated with Developmental and Epileptic Encephalopathies (DEEs) for patients two years of age or